Arbutus Biopharma Corporation
Arbutus Biopharma Corporation (ABUS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ABUS · as of Sep 30, 2025
Ownership Breakdown
184
Institutional Holders
▲ 9 vs Q2
$536.43M
Total Inst. Value
▲ $171.47M vs Q2
197.54M
Shares Outstanding
freeFloat 79.48%
118.18M
13F Shares Held
▲ 70,541 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ABUS largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
MORGAN STANLEY pharmaceutical preparations | 24.45M | 12.76% | 12.76% | $111.01B | May 27, 2026 | ▲ 288.2K |
WHITEFORT CAPITAL MANAGEMENT, LP pharmaceutical preparations | 13.34M | 6.97% | 6.97% | $60.58B | Nov 14, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 12.68M | 6.62% | 6.62% | $57.56B | Nov 12, 2025 | ▼ 191.8K |
TWO SEAS CAPITAL LP pharmaceutical preparations | 10.99M | 5.74% | 5.74% | $49.90B | Nov 14, 2025 | ▲ 547.9K |
VANGUARD GROUP INC pharmaceutical preparations | 8.99M | 4.69% | 4.69% | $40.82B | Nov 7, 2025 | ▼ 94.0K |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 5.01M | 2.62% | 2.62% | $22.77B | Nov 14, 2025 | ▲ 2.44M |
STATE STREET CORP pharmaceutical preparations | 4.10M | 2.14% | 2.14% | $18.61B | Nov 14, 2025 | ▼ 361.4K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 3.67M | 1.91% | 1.91% | $16.65B | Nov 12, 2025 | ▲ 29.1K |
ADAR1 CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 2.90M | 1.52% | 1.52% | $13.18B | Nov 14, 2025 | ▲ 77.5K |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 2.17M | 1.13% | 1.13% | $9.87B | Nov 14, 2025 | ▼ 866.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
23
Increased
+5.88M shares4
New Positions
first time holders18
Decreased
−4.66M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.21M
+5.88M / −4.66M
Net new holders
+9
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ABUS insider trading · insider activity
Source: SEC Form 4
4
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Nguyen Tuan Chief Financial Officer | Feb 2, 2026 | Award | 188,400 | $4.39 | $827.1K | 188.4K | Form 4 ↗ |
Nguyen Tuan Chief Financial Officer | Feb 2, 2026 | Award | 73,500 | — | — | 73.5K | Form 4 ↗ |
Androski Lindsay President and CEO | Feb 2, 2026 | Award | 71,700 | $4.39 | $314.8K | 71.7K | Form 4 ↗ |
Androski Lindsay President and CEO | Feb 2, 2026 | Award | 28,000 | — | — | 28.0K | Form 4 ↗ |
Sawhney Roger director | Aug 4, 2025 | Award | 157,600 | $3.34 | $526.4K | 157.6K | Form 4 ↗ |
Nguyen Tuan Chief Financial Officer | Mar 31, 2025 | Award | 750,000 | $3.49 | $2.62M | 750.0K | Form 4 ↗ |
Nguyen Tuan Chief Financial Officer | Mar 31, 2025 | Award | 750,000 | $3.50 | $2.63M | 750.0K | Form 4 ↗ |
Hasija Anuj director | Mar 18, 2025 | Award | 157,600 | $3.20 | $504.3K | 157.6K | Form 4 ↗ |
Beardsley Robert A director | Mar 18, 2025 | Award | 157,600 | $3.20 | $504.3K | 157.6K | Form 4 ↗ |
Androski Lindsay President and CEO | Mar 18, 2025 | Award | 310,422 | $3.20 | $993.4K | 310.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Arbutus Biopharma Corporation (ABUS) is primarily owned by institutional investors, who hold approximately 59.8% of total shares outstanding. Company insiders own approximately 20.52%, while retail and public investors account for the remaining 19.65%.
The largest institutional shareholder of Arbutus Biopharma Corporation is MORGAN STANLEY, holding approximately 24.45 million shares — equal to 12.76% of outstanding shares — as of September 30, 2025.
A total of 184 institutional investors currently hold ABUS stock, with a combined institutional value of approximately $536,434,901 as of the most recent 13F filing period.
Frequently asked questions
ABUS ownershipArbutus Biopharma Corporation (ABUS) is primarily owned by institutional investors, who hold approximately 59.8% of shares. The largest shareholder is MORGAN STANLEY with a 12.76% stake. Company insiders hold 20.52%. Data sourced from SEC Form 13F as of September 30, 2025.